Comment: treatment of heparin-induced thrombocytopenia.
Smythe
Maureen A
MA
Warkentin
Theodore E
TE
D000925:Anticoagulants / Q000009:adverse effects*; D001120:Arginine / Q000031:analogs & derivatives; D006493:Heparin / Q000009:adverse effects*; D006629:Hirudins / Q000031:analogs & derivatives*; D006801:Humans; D019934:International Normalized Ratio; D010875:Pipecolic Acids / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D014859:Warfarin / Q000009:adverse effects
D000925:Anticoagulants; D006629:Hirudins; D010875:Pipecolic Acids; D011994:Recombinant Proteins; D013449:Sulfonamides; D014859:Warfarin; D006493:Heparin; D001120:Arginine; D013917:Thrombin; C031942:argatroban; C083544:lepirudin